U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H33ClN2O5S.ClH.H2O
Molecular Weight 479.459
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLINDAMYCIN HYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.[H][C@@](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)([C@H](C)Cl)[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O

InChI

InChIKey=KWMXKEGEOADCEQ-WNNJHRBUSA-N
InChI=1S/C18H33ClN2O5S.ClH.H2O/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4;;/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25);1H;1H2/t9-,10+,11-,12+,13-,14+,15+,16+,18+;;/m0../s1

HIDE SMILES / InChI

Molecular Formula C18H33ClN2O5S
Molecular Weight 424.983
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm

Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents

CNS Activity

Curator's Comment: Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN T

Approved Use

Clindamycin Phosphate is indicated in the treatment of acne vulgaris.

Launch Date

3.31862409E11
Curative
CLEOCIN PHOSPHATE

Approved Use

Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.

Launch Date

8.6745596E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 μg/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.92 ng/mL
0.03 g 1 times / day steady-state, topical
dose: 0.03 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.2 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.54 ng × h/mL
0.03 g 1 times / day steady-state, topical
dose: 0.03 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 g 7 times / day multiple, vaginal
Recommended
Dose: 5 g, 7 times / day
Route: vaginal
Route: multiple
Dose: 5 g, 7 times / day
Sources: Page: p.571
unhealthy, 16 - 51
n = 79
Health Status: unhealthy
Condition: Bacterial Vaginosis
Age Group: 16 - 51
Sex: F
Population Size: 79
Sources: Page: p.571
Disc. AE: Vaginal pain or burning...
AEs leading to
discontinuation/dose reduction:
Vaginal pain or burning (1.2%)
Sources: Page: p.571
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Disc. AE: Diarrhea, Clostridium difficile, Reaction skin...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Reaction skin (severe)
Toxic epidermal necrolysis (grade 3-5)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Vaginal pain or burning 1.2%
Disc. AE
5 g 7 times / day multiple, vaginal
Recommended
Dose: 5 g, 7 times / day
Route: vaginal
Route: multiple
Dose: 5 g, 7 times / day
Sources: Page: p.571
unhealthy, 16 - 51
n = 79
Health Status: unhealthy
Condition: Bacterial Vaginosis
Age Group: 16 - 51
Sex: F
Population Size: 79
Sources: Page: p.571
Anaphylactic shock Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Hypersensitivity reaction severe
Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Anaphylactic shock Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Hypersensitivity reaction severe
Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Anaphylactic shock Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Hypersensitivity reaction severe
Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Toxic epidermal necrolysis grade 3-5
Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Reaction skin severe
Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
likely (co-administration study)
Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin
Page: 5.0
minor
likely (co-administration study)
Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin
Page: 5.0
not determined
not determined
not determined
not determined
not determined
not determined
not determined
not determined
PubMed

PubMed

TitleDatePubMed
Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.
1999 Sep
Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis.
2001
Thoracic spondylitis mimicking idiopathic scoliosis: a case report.
2001 Apr
Laparoscopic management of adnexal masses.
2001 Apr-Jun
Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction.
2001 Feb
The development of antibiotic resistance in Propionibacterium acnes.
2001 Feb
Antibiotic susceptibility of Kingella kingae isolates from respiratory carriers and patients with invasive infections.
2001 Feb
Clostridium difficile colitis following antibiotic prophylaxis for dental procedures.
2001 Jan
Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study.
2001 Jan
Toxoplasmosis, a severe complication in allogeneic hematopoietic stem cell transplantation: successful treatment strategies during a 5-year single-center experience.
2001 Jan
Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents.
2001 Jul
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.
2001 Jul
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.
2001 Jun
[Chronic osteomyelitis of the ilium after autologous bone harvesting in Albers-Schonberg osteopetrosis. A case report].
2001 Jun
Infection of hamsters with epidemiologically important strains of Clostridium difficile.
2001 Jun 15
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.
2001 Mar
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998.
2001 Mar
Antibiotic-resistant bacteria in pediatric chronic sinusitis.
2001 Mar
Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children.
2001 Mar
Molecular epidemiology and genetic linkage of macrolide and aminoglycoside resistance in Staphylococcus intermedius of canine origin.
2001 Mar 20
High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda.
2001 May
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001 May 15
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
2001 May-Jun
Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis.
2001 May-Jun
Isolation and antimicrobial susceptibility testing of fecal strains of the archaeon Methanobrevibacter smithii.
2001 May-Jun
Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones.
2001 Spring
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.
2001 Spring
Erythromycin and amoxicillin?
2001 Winter
Preparation and characterization of chitosan-based spray-dried microparticles for the delivery of clindamycin phosphate to periodontal pockets.
2014
Patents

Sample Use Guides

150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The Minimum Inhibitory Concentration was 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619) when testing aerobic pathogens and 0.06-0.25 ug/ml (Eubacterium lentum ATCC 43055) when testing anaerobs.
MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:59:19 UTC 2023
Edited
by admin
on Wed Jul 05 23:59:19 UTC 2023
Record UNII
ZNC153389R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLINDAMYCIN HYDROCHLORIDE MONOHYDRATE
MI  
Common Name English
CLINDAMYCIN HYDROCHLORIDE MONOHYDRATE [MI]
Common Name English
CLINDAMYCIN HYDROCHLORIDE HYDRATE
Common Name English
CLINDAMYCIN MONOHYDROCHLORIDE MONOHYDRATE
WHO-DD  
Common Name English
L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, MONOHYDROCHLORIDE, MONOHYDRATE,(2S-TRANS)-
Systematic Name English
Clindamycin monohydrochloride monohydrate [WHO-DD]
Common Name English
METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(1-METHYL-TRANS-4-PROPYL-L-2-PYRROLIDINECARBOXAMIDO)-1-THIO-L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE MONOHYDROCHLORIDE, MONOHYDRATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C82922
Created by admin on Wed Jul 05 23:59:19 UTC 2023 , Edited by admin on Wed Jul 05 23:59:19 UTC 2023
Code System Code Type Description
PUBCHEM
53302336
Created by admin on Wed Jul 05 23:59:19 UTC 2023 , Edited by admin on Wed Jul 05 23:59:19 UTC 2023
PRIMARY
MERCK INDEX
M3624
Created by admin on Wed Jul 05 23:59:19 UTC 2023 , Edited by admin on Wed Jul 05 23:59:19 UTC 2023
PRIMARY
EVMPD
SUB31635
Created by admin on Wed Jul 05 23:59:19 UTC 2023 , Edited by admin on Wed Jul 05 23:59:19 UTC 2023
PRIMARY
CAS
58207-19-5
Created by admin on Wed Jul 05 23:59:19 UTC 2023 , Edited by admin on Wed Jul 05 23:59:19 UTC 2023
PRIMARY
FDA UNII
ZNC153389R
Created by admin on Wed Jul 05 23:59:19 UTC 2023 , Edited by admin on Wed Jul 05 23:59:19 UTC 2023
PRIMARY
NCI_THESAURUS
C83630
Created by admin on Wed Jul 05 23:59:19 UTC 2023 , Edited by admin on Wed Jul 05 23:59:19 UTC 2023
PRIMARY
SMS_ID
100000124213
Created by admin on Wed Jul 05 23:59:19 UTC 2023 , Edited by admin on Wed Jul 05 23:59:19 UTC 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY